GlassScriptPhysician profile
Zia Roshandel
NPI 1295776995
$1,891.14
in general payments reported to CMS, 2019-2025
17 companies · $159 in 2025
The $159 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $316 · 2020: $267 · 2021: $275 · 2022: $339 · 2023: $253 · 2024: $282 · 2025: $159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $694.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $694.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $359.74 | 2019-2023 | Jardiance |
| Boston Scientific Corporation | $273.30 | 2021-2025 | Watchman Flx |
| E.R. Squibb & Sons, L.L.C. | $184.75 | 2019-2025 | Camzyos |
| Irhythm Technologies, INC. | $180.31 | 2020-2024 | Zio Xt Patch, Zio Monitor |
| Novartis Pharmaceuticals Corporation | $155.63 | 2019-2023 | |
| Amgen INC. | $126.56 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $115.26 | 2021-2024 | Xarelto |
| Medicomp INC | $114.53 | 2023-2025 | Telepatch Cardiac Monitor |
| Astrazeneca Pharmaceuticals LP | $99.63 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $68.45 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $47.09 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $45.10 | 2020-2021 | |
| Pfizer INC. | $42.17 | 2019-2020 | |
| Novo Nordisk INC | $33.09 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Atricure, INC. | $19.01 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bardy Diagnostics, INC. | $14.40 | 2020 | |
| Abbott Laboratories | $12.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zia Roshandel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.